[go: up one dir, main page]

WO2004021999A3 - Use of histamine h4 receptor modulators for the treatment of allergy and asthma - Google Patents

Use of histamine h4 receptor modulators for the treatment of allergy and asthma Download PDF

Info

Publication number
WO2004021999A3
WO2004021999A3 PCT/US2003/027943 US0327943W WO2004021999A3 WO 2004021999 A3 WO2004021999 A3 WO 2004021999A3 US 0327943 W US0327943 W US 0327943W WO 2004021999 A3 WO2004021999 A3 WO 2004021999A3
Authority
WO
WIPO (PCT)
Prior art keywords
histamine
receptor modulators
asthma
treatment
allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/027943
Other languages
French (fr)
Other versions
WO2004021999A2 (en
Inventor
Pragnya J Desai
Paul J Dunford
Claudia L Hofstra
Lars Karlsson
Wai-Ping Leung
Ping Ling
Robin L Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to CA002497788A priority Critical patent/CA2497788A1/en
Priority to EP03794649A priority patent/EP1545596A4/en
Priority to JP2004534688A priority patent/JP2006510590A/en
Priority to MXPA05002577A priority patent/MXPA05002577A/en
Priority to AU2003265961A priority patent/AU2003265961A1/en
Publication of WO2004021999A2 publication Critical patent/WO2004021999A2/en
Publication of WO2004021999A3 publication Critical patent/WO2004021999A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are disclosed for identifying histamine receptor modulators that affect mast cell or basophil chemotaxis, and the use of such histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of asthma and/or allergic responses, or diseases and/or conditions that are modulated, affected or caused by asthma or allergic responses. Also disclosed is the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of mast cell or basophil chemotactic responses, such as migration to a particular site, or diseases and/or conditions that are modulated, affected or caused by mast cell or basophil chemotaxis.
PCT/US2003/027943 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma Ceased WO2004021999A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002497788A CA2497788A1 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
EP03794649A EP1545596A4 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
JP2004534688A JP2006510590A (en) 2002-09-06 2003-09-05 Use of histamine H4 receptor modulators for the treatment of allergies and asthma
MXPA05002577A MXPA05002577A (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma.
AU2003265961A AU2003265961A1 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40873602P 2002-09-06 2002-09-06
US60/408,736 2002-09-06

Publications (2)

Publication Number Publication Date
WO2004021999A2 WO2004021999A2 (en) 2004-03-18
WO2004021999A3 true WO2004021999A3 (en) 2004-10-07

Family

ID=31978667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027943 Ceased WO2004021999A2 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Country Status (6)

Country Link
EP (1) EP1545596A4 (en)
JP (1) JP2006510590A (en)
AU (1) AU2003265961A1 (en)
CA (1) CA2497788A1 (en)
MX (1) MXPA05002577A (en)
WO (1) WO2004021999A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520644A (en) * 2004-11-24 2008-06-19 ファイザー・インク Octahydropyrrolo [3,4-c] pyrrole derivative
EP1671972A1 (en) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole compounds
JP5306818B2 (en) * 2006-10-18 2013-10-02 武田薬品工業株式会社 Fused heterocyclic compounds
KR100954138B1 (en) * 2007-12-31 2010-04-20 부산대학교 산학협력단 Allergic rhinitis or asthma prevention and treatment containing adipose tissue-derived stem cells
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
JP2012102017A (en) * 2009-03-03 2012-05-31 Astellas Pharma Inc Indole compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085786A2 (en) * 2000-05-05 2001-11-15 Wyeth Human histamine h4 receptor
WO2001092485A1 (en) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
WO2002056871A2 (en) * 2001-01-17 2002-07-25 Pfizer Limited Histamine receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008143A (en) * 2001-03-09 2005-08-16 Johnson & Johnson Heterocyclic compounds.
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
US20040132715A1 (en) * 2002-09-06 2004-07-08 Dunford Paul J. Method to treat allergic rhinitis
AU2003265886A1 (en) * 2002-09-06 2004-03-29 Janssen Pharmaceutica N.V. (1H-Benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085786A2 (en) * 2000-05-05 2001-11-15 Wyeth Human histamine h4 receptor
WO2001092485A1 (en) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
WO2002056871A2 (en) * 2001-01-17 2002-07-25 Pfizer Limited Histamine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1545596A4 *

Also Published As

Publication number Publication date
EP1545596A4 (en) 2005-12-28
EP1545596A2 (en) 2005-06-29
JP2006510590A (en) 2006-03-30
CA2497788A1 (en) 2004-03-18
WO2004021999A2 (en) 2004-03-18
AU2003265961A1 (en) 2004-03-29
MXPA05002577A (en) 2005-09-20

Similar Documents

Publication Publication Date Title
PT1543011E (en) COMPOSITION OF TIENOPYROLYL AND FURANOPYROLYL AND ITS USE AS LIGANDS OF HISTAMINE H4 RECEPTOR
BR0314059A (en) Heterocyclic compounds
WO2004018058A3 (en) Compounds, compositions, and methods
WO2003094839A8 (en) Pyrimidinone compounds, compositions and methods
DE50213336D1 (en) SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINE AND ITS USE
BRPI0507462A (en) substituted quinoline compounds
WO2006015124A3 (en) Fused ring heterocycle kinase modulators
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
BRPI0513916A (en) pyrrol pyridine kinase modulators
EP1461352A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF BIND WEIGHT GROWTH FACTOR
DE60317093D1 (en) quinoline; ISOCHINOLIN AND CHINAZOLINE OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES
WO2003088903A3 (en) Compounds, compositions, and methods
AU2003270626A1 (en) Magnetically modified electrodes as well as methods of making and using the same
DE60311467D1 (en) DISPERSION OF WATER-SOLUBLE POLYMER, METHOD OF MANUFACTURING THEREOF AND USE METHOD THEREFOR
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
WO2004009036A3 (en) Compounds compositions and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004021999A3 (en) Use of histamine h4 receptor modulators for the treatment of allergy and asthma
WO2004064741A3 (en) Compounds, compositions, and methods
DK1397681T3 (en) Method of identifying agents for the treatment of diabetes
MXPA05001885A (en) The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis.
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
AU2003267731A1 (en) Argyrolobium roseum plant extracts for treating diabetes
WO2003057919A3 (en) The use of histamine h4 receptor antagonist for the treatment of inflammatory response
WO2004024086A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003265961

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004534688

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2497788

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/002577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003794649

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003794649

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003794649

Country of ref document: EP